1

About ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC)

News Discuss 
These side effects ended up notably milder compared to an inhibitor of the two bromodomains. A detailed molecular analysis also exposed that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes.  ― Stephen Taylor - "Our study uncovered the essential job in the KLF16/MYC regulatory axis in modulating tumor https://boysx222obm6.bmswiki.com/user

Comments

    No HTML

    HTML is disabled


Who Upvoted this Story